Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04566003 · ClinicalTrials.gov registry record · Phase 1
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04566003 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 40 participants.
The verdict
NCT04566003, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study aims to compare tau targeted radiotracers \[18F\]GTP1 and \[18F\]PI-2620 or \[18F\]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
Interventions
- DRUG [18F]PI-2620
- DRUG [18F]GTP1
- DRUG [18F]MK-6240
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2023-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04566003
The ClinicalTrials.gov registry entry for NCT04566003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which [18F]PI-2620 is the first listed.
NCT04566003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04566003 about?
NCT04566003 is a clinical study titled "Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease". The study aims to compare tau targeted radiotracers \[18F\]GTP1 and \[18F\]PI-2620 or \[18F\]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
What is the current status of trial NCT04566003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-10-26. Estimated completion is 2023-06-27.
What interventions are being tested in trial NCT04566003?
The interventions under investigation include: [18F]PI-2620 (DRUG), [18F]GTP1 (DRUG), [18F]MK-6240 (DRUG).
Who is sponsoring clinical trial NCT04566003?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.